Category: Civica

  • Civica plans shake-up of insulin sector with low-cost biosimilars

    Non-profit drugmaker Civica Rx has said it will launch biosimilars of three big-selling insulin products in the US by 2024 to help diabetic patients struggling with the cost of the drugs. First launched in 2018 to to tackle shortages in lifesaving medicines and improve the affordability of drugs, Civica has now teamed up with a […]